| Literature DB >> 35910049 |
Faten Fedhila1, Sarra Ben Ahmed1, Elhem Jbebli1, Fatma Mezghani1, Samir Haddad1, Samar Rhayem1, Monia Khemiri1.
Abstract
Chemotherapy-induced neutropenia (FN) is the most common infectious complication in pediatric oncology. To our knowledge, no pediatric research has been published in Tunisia. The purpose of our study was to describe the features of FN among Tunisian children and to investigate factors correlated with FN. We conducted a prospective study of children with chemotherapy-induced FN at the Department of Pediatric Medicine A of the Tunis Children´s Hospital from July 2019 to December 2019. We recorded 50 episodes of FN in 32 patients whose mean age was 5.3 years (3 months-16 years). We included 26 patients with solid tumors (81%) and six patients with hemopathies (18.7%). The mean time between last treatment and fever onset was 10.67 days. Bacteriological investigation was contributory in 18% of cases and mainly showed gram positive cocci. Therapeutic protocol including 1st line empirical antibiotic therapy (3rd generation cephalosporin with aminoglycoside) was effective in 62% of cases. Mortality rate of patients with FN was 2%. The statistical study did not reveal any factor of correlation with late-onset neutropenia. In conclusion, our results are consistent with literature data on bacteriological documentation and mortality. Our 1st line treatment option based on 3rd generation cephalosporin associated with aminoglycoside was effective in 2/3 of the cases. In the future, oral antibiotics may be considered in patients at low risk for infection. Copyright: Faten Fedhila et al.Entities:
Keywords: Febrile neutropenia; chemotherapy; microbiology; pediatric; tumors
Mesh:
Substances:
Year: 2022 PMID: 35910049 PMCID: PMC9288120 DOI: 10.11604/pamj.2022.42.34.28176
Source DB: PubMed Journal: Pan Afr Med J
Figure 1algorithme décisionnel de l´antibio thérapie probabiliste
Figure 2répartition des patients en fonction du type de pathologie
répartition des anomalies retrouvées à l´examen clinique
| Signes cliniques | N=50 | Pourcentage(%) | ||
|---|---|---|---|---|
|
| Mucite | grade 1 | 5 | 32 |
| grade 2 | 5 | |||
| grade 3 | 6 | |||
| Cellulite | Cellulite orbitaire | 1 | 4 | |
| Cellulite de la cuisse droite | 1 | |||
| Marbrures | 1 | 2 | ||
| Aphtes buccaux | 1 | 2 | ||
| Conjonctivite | 1 | 2 | ||
| Issue de pus par une plaie | 1 | 2 | ||
|
| Angine | 2 | 4 | |
|
| Etat de choc hypovolémique | 1 | 2 | |
|
| Râles crépitants à l´auscultation | 1 | 2 | |
|
| Ballonnement abdominal avec sensibilité abdominale | 1 | 2 | |
répartition des germes en fonction du site d´isolement
| Hémocultures n=50 | Coprocultures n=4 | Prélèvements cutanés n=2 | ||||
|---|---|---|---|---|---|---|
| Staphylocoque coagulase négative | 3 | Salmonella | 1 | Staphylocoque coagulase négative | 1 | |
| Entérocoque | 1 | |||||
| Klebsiella Pneumoniae BLSE | 1 | |||||
|
| Alcaligenes Denitrificans | 1 | Négatives | 3 | Négatif | 1 |
| Salmonella | 1 | Négatives | 3 | Négatif | 1 | |
| Négatives | 48 | |||||
BLSE : Bétalactamase à spectre élargi